Adjunct Associate Professor
Mediphase Venture Partners, L.P.
2150 Washington Street, Suite 200
Newton, MA 02462
Phone: 617) 332-3408
Email:Lgmiller@mediphaseventure.com

Dr. Miller is a long-time expert on the behavioral and neurochemical effects of acute and chronic benzodiazepine administration. Presently he is the manager of a venture capital fund which invests primarily in biotechnology companies.

Previous Publications:

Koff JM, Pritchard GA, Greenblatt DJ, Miller LG. The NMDA receptor competitive antagonist CPP modulates benzodiazepine tolerance and discontinuation. Pharmacology 55(5):217-27, 1997.

Koff JM, Miller LG. Prenatal lorazepam exposure: 4. Persistent alterations in pentylenetetrazole-induced seizure threshold and GABA-dependent chloride uptake after prenatal lorazepam exposure. Pharmacol Biochem Behav 51(4):721-4, 1995.

Fahey JM, Lindquist DG, Pritchard GA, Miller LG. Pregnenolone sulfate potentiation of NMDA-mediated increases in intracellular calcium in cultured chick cortical neurons. Brain Res 669(2):183-8, 1995.

Miller LG, Koff JM. Interaction of central and peripheral benzodiazepine sites in benzodiazepine tolerance and discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 18(5):847-57, 1994.